IMPLICATIONS OF BIODEGRADABLE AND BIOADHESIVE SYSTEMS IN COLON DELIVERY
Abstract
Oral or non-parental drug delivery systems are widely used for the administration of therapeutic drugs. However, the gastrointestinal tract presents several barriers to anticancer drugs in targeting colon cancer. Colonic drug delivery has gained increased importance not just for the delivery of the drugs for the treatment of local diseases associated with the colon but also for its potential for the delivery of proteins and therapeutic peptides. To achieve successful colonic delivery, which is considered to be the optimum site for colon-targeted delivery of drugs, colon targeting is of prime importance for the topical treatment of diseases of colon such as Chorn's diseases, ulcerative colitis, colorectal cancer and amebiasis. Peptides, proteins, oligonucleotides and vaccines pose potential candidature for colon targeted drug delivery.
Keywords:
Anticancer drugs, Chorn's diseases, amebiasisDOI
https://doi.org/10.25004/IJPSDR.2009.010201References
Sarasija S, Hota A. Colon-specific drug delivery systems. Ind J Pharm Sci 2000; 62: 1-8.
Basit AW. Advances in colonic drug delivery. Drugs 2005; 65: 1991–2007.
Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci 2003; 6 (1): 33-66.
Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Del Rev 2005; 57: 267–79.
Jain A, Gupta Y, Jain SK. Azo-chemistry and its potential for colonic delivery. Crit. Rev. Ther. Drug Carrier Syst 2006; 23(5): 349-400.
Nutrition and Health Educator, Inc. DBA Nutrigenesis Approach. Available at, http.//www.nutrigenesis.com/page_images/Digestive_XL.jpg. Accessed July 27, 2006.
Rubinstein A. Colonic drug delivery. Drug Discov Today: Technol 2005; 2(1): 33–7.
Gruber P, Longer MA, Robinson JR. Some biological issues in oral, controlled drug delivery. Adv Drug Del Rev 1987; 1: 1.
Simon GL, Gorbach SL. Bacteriology of the colon, in Colon, Structure and Function, Bustos-Fernandez, L. Ed. Plenum Medical Book Company, New York, 1983, pp. 103.
Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pham Pharmacol 1985; 37: 874.
Evans DF, Pye G, Bramley R, Clark, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 1035.
Kenyon CJ, Cole ET, Wilding IR. The effect of food on the in vivo behavior of enteric coated starch capsules. Int J Pharmacol 1994; 112: 207.
Adkin DA, Davis SS, Sparrow RA, Wilding IR. Colon transit of different sized tablets in healthy subjects. J Control Rel 1993; 23: 147.
Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br. J Clin Pharmacol 1982; 14: 405.
Thomas P, Richards D, Richards A, Rogers L, Evans BK, Dew MJ, Rhodes J. Absorption of delayed release dependent polymers for colonic targeting. Int J Pharmacol 1985; 37: 757
Raffi R, Franklin W, Cernigila CE. Azoreductase activity of anaerobic bacteria isolated from human intertinal microflora. Appl Environ Microbiol 1990; 56: 2146-2151.
Raffi R, Franklin W, Heflich RH, Cerniglia CE. Reduction of nitroaromatic compounds by anaerobic bacteria isolated from human intestinal tract. Appl Environ Microbiol 1991; 57: 962-968.
Walker R, Ryan AJ. Some molecular parameters influencing rate of reduction of Azo compounds by Intestinal microflora. Xenobiotica 1971; 1: 483-486.
Azad Khan AK, Truelove SK, Aronseq JK. The disposition and metabolism of sulphasalazine (salicylazo-sulphapyridine) in man. Br J Clin Pharmacol1982; 13: 523-528.
Chanm RP, Pope DJ, Gilbert AP, Baron JH, Lennard-jones JP. Studies of two novel sulfaslazine analogue: ipsalazine and balsalazine. Dig Dis Sci 1983; 28: 609-615.
Hartalsky A. Salicylazobenzonic acid in ulcerative colitis. Lancet 1982; 1: 960.
Garreto M, Ridell RH, Wurans CS. Treatment of chronic ulcerative colitis with poly-ASA: A new nonabosrbable carrier for release of 5-aminosalicylic acid in the colon. Gastroenterology 1981; 84: 1162.
Willoughby CP, Aronson JK, Agback H, Bodin NO, Anderson E, Truelove SC. Disposition in normal volunteers of sodium azodisalicylate, a potential therapeutic agent in inflammatory bowl disease. Gut 1981; 22: A431.
Willoughby CP, Aronson JK, Agback H, Bodin NO, Anderson E, Truelove S. Disposition in normal volunteers of sodium azodisalicylate, a potential therapeutic agent in ulcerative colitis. Gut 1982; 23: 1081-1087.
Lauristein K, Hansen J, Ryde HM, Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984; 86: 1496-1500.
Published
Abstract Display: 198 
PDF Downloads: 381 How to Cite
Issue
Section
Copyright (c) 2009 Dinesh Kaushik, Satish Sardana, Dina Nath Mishra
This work is licensed under a Creative Commons Attribution 4.0 International License.
